Profile data is unavailable for this security.
About the company
XOMA Royalty Corporation, formerly XOMA Corporation, is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
- Revenue in USD (TTM)15.24m
- Net income in USD-25.10m
- Incorporated2011
- Employees13.00
- LocationXOMA Royalty Corp2200 Powell Street, Suite 310EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 204-7239
- Fax+1 (302) 655-5049
- Websitehttps://www.xoma.com/
Mergers & acquisitions
Acquired company | XOMA:NMQ since announced | Transaction value |
---|---|---|
Kinnate Biopharma Inc | 27.10% | 99.33m |